Drug intelligence / Profile preview

EVD-006

Development stage: Preclinical
Lead developer: Evozyne
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

EVD-006 is an engineered cytokine currently in the discovery stage, developed by Evozyne for the treatment of autoimmune diseases. Utilizing Evozyne's proprietary protein engineering platform, EVD-006 is designed to decouple anti-inflammatory signaling from unwanted pro-inflammatory effects. This selective signaling approach aims to provide a more targeted and safer therapeutic option for patients with chronic immune-mediated disorders by optimizing the cytokine's interaction with its specific receptors. As of early 2024, the candidate is part of a broader portfolio of engineered cytokines advancing toward clinical development.

Targets

Cr (Chromium)

Beyond the preview

Go deeper on EVD-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVD-006.

Explore the full profile